A new twice-yearly HIV prevention injection could transform South Africa's fight against the epidemic — but U.S. aid cuts and limited doses threaten to slow its impact.

Limited supplies threaten potential positive effect of HIV prevention drug lenacapavir

Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa